Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 14 of 33, showing 5 Applications out of 165 total, starting on record 66, ending on 70

# Protocol No Study Title Investigator(s) & Site(s)

66.

ECCT/20/07/03   STAND
    A Phase III multicenter, randomized, double blind study to assess efficacy and safety of two doses of crizanlizumab verses placebo, with or without hydroxyurea/hydroxycarbamide therapy in adolescent and adult sickle cell disease patients with Vaso-Occlusive Crises (STAND)   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
Site(s) in Kenya
1. CREATES Strathmore University (Nairobi City county)
2. Getrudes Childrens Hospital (Nairobi City county)
3. International Cancer Institute (Elgeyo/Marakwet county)
 
View

67.

ECCT/20/08/02   ALIVE study
    Evaluation of the effectiveness of IVERMECTIN co-formulation vs ALBENDAZOLE for treatment of for the Treatment of Soil-Transmitted Helminth Infections (Trichuris trichiura, hookworm, Strongyloides stercoralis) in school aged children and Young Adult Subjects (ALIVE Study)   
Principal Investigator(s)
1. Charles Mwandawiro
Site(s) in Kenya
Kwale
 
View

68.

ECCT/20/09/02   BEe-HIVe
     B-ENHANCEMENT OF HBV VACCINATIONIN PERSONS LIVING WITH HIV (BEe-HIVe) EVALUATION OF HEPLISAV-B,A5379   
Principal Investigator(s)
1. JOSPHAT KOSGEI
Site(s) in Kenya
KEMRI/KERICHO CLINIC RESEARCH CENTRE
 
View

69.

ECCT/20/10/02   MALCOV
    Malaria as a risk factor for COVID-19 in western Kenya and Burkina Faso (MALCOV)   
Principal Investigator(s)
1. Simon Kariuki
2. Helen Barsosio
Site(s) in Kenya
1. Jaramogi Oginga Odinga Teaching and Referral Hospital (JOORTH), (Kisumu county)
2. Kisumu County Referral Hospital. (Kisumu county)
3. Alupe sub-County Hospital, (Busia county)
4. Bondo sub-County Hospital, (Siaya county)
5. Macalder (Nyatike) sub-County Hospital (Migori county)
6. Migori County Teaching and Referral Hospital; (Migori county)
 
View

70.

ECCT/20/10/04   yellow fever vaccine CVIA 079
    A Phase III double-blind, randomized, active comparator controlled study in healthy Kenyan adolescents, young children and infants to assess the safety and immunogenicity of Beijing Institute of Biologic Products (BIBP) yellow fever vaccine in comparison to a WHO 17D-204 prequalified comparator yellow fever vaccine, as well as lot-to-lot consistency of immune response to the BIBP yellow fever vaccine”, CVIA 079.   
Principal Investigator(s)
1. Dr. Deborah Langat
Site(s) in Kenya
KEMRI/KERICHO CLINIC RESEARCH CENTRE
 
View